These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7726124)

  • 1. Clinical pharmacology of nisoldipine coat core.
    Zannad F
    Am J Cardiol; 1995 Apr; 75(13):41E-45E. PubMed ID: 7726124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation.
    Heinig R; Ahr G; Hayauchi Y; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):341-51. PubMed ID: 9266290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nisoldipine coat-core. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of ischaemic heart disease.
    Langtry HD; Spencer CM
    Drugs; 1997 May; 53(5):867-84. PubMed ID: 9129871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid-release and coat-core formulations of nisoldipine in treatment of hypertension, angina, and heart failure.
    Hamilton SF; Houle LM; Thadani U
    Heart Dis; 1999; 1(5):279-88. PubMed ID: 11720635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nisoldipine CC: clinical experience in hypertension.
    Langan J; Rodríguez-Mañas L; Sareli P; Heinig R
    Cardiology; 1997; 88 Suppl 1():56-62; discussion 63-5. PubMed ID: 9118169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form.
    Schaefer HG; Heinig R; Ahr G; Adelmann H; Tetzloff W; Kuhlmann J
    Eur J Clin Pharmacol; 1997; 51(6):473-80. PubMed ID: 9112062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nisoldipine CC: efficacy and tolerability in hypertension and ischemic heart disease.
    Fodor JG
    Cardiovasc Drugs Ther; 1997 Jan; 10 Suppl 3():873-9. PubMed ID: 9126676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of nisoldipine coat-core formulation in the treatment of essential hypertension: The South African Multicenter ANCHOR Study. Ambulatory Nisoldipine Coat-Core Hypertension Outpatient Response (ANCHOR) Investigators.
    Opie LH; Müller FO; Myburgh DP; Rosendorff C; Sareli P; Seedat YK; Weich DJ; Luus HG
    Am J Hypertens; 1997 Mar; 10(3):250-60. PubMed ID: 9056681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nisoldipine coat-core. A review of its pharmacology and therapeutic efficacy in hypertension.
    Plosker GL; Faulds D
    Drugs; 1996 Aug; 52(2):232-53. PubMed ID: 8841741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nisoldipine coat core as concomitant therapy in chronic stable angina pectoris.
    Glasser SP
    Am J Cardiol; 1995 Apr; 75(13):68E-70E. PubMed ID: 7726128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics of nisoldipine coat-core.
    Heinig R
    Clin Pharmacokinet; 1998 Sep; 35(3):191-208. PubMed ID: 9784933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nisoldipine coat-core and heart rate response during treatment of hypertension.
    Zannad F
    Int J Clin Pract; 1999; 53(1):65-71. PubMed ID: 10344070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of nisoldipine coat core in the management of angina pectoris, systemic hypertension, and ischemic ventricular dysfunction.
    Lewis BS
    Am J Cardiol; 1995 Apr; 75(13):46E-53E. PubMed ID: 7726125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nisoldipine: a new dihydropyridine calcium-channel blocker.
    Mitchell J; Frishman W; Heiman M
    J Clin Pharmacol; 1993 Jan; 33(1):46-52. PubMed ID: 8429113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Responses of plasma eicosanoids and hemodynamics to myocardial ischemia and the salutary effect of calcium entry blocker].
    Takase B
    Nihon Ika Daigaku Zasshi; 1990 Feb; 57(1):42-54. PubMed ID: 2329180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What does nisoldipine coat core (CC) add to current therapy that is clinically meaningful?
    Opie LH
    Am J Cardiol; 1997 May; 79(10A):29-32; discussion 47-8. PubMed ID: 9186064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved diastolic function with the calcium antagonist nisoldipine (coat-core) in patients post myocardial infarction: results of the DEFIANT study. Doppler Flow and Echocardiography in Functional cardiac Insufficiency: Assessment of Nisoldipine Therapy.
    Eur Heart J; 1992 Nov; 13(11):1496-505. PubMed ID: 1464339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of the acute hemodynamic effect of nisoldipine (Bay k 5552) and nifedipine in patients with ischemia-induced left ventricular impaired function].
    Aschenberg W; Nienaber C; Spielmann R; Bleifeld W
    Z Kardiol; 1988 Apr; 77(4):238-44. PubMed ID: 3291444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Myocardial effects of the calcium antagonists nifedipine, nisoldipine and isradipine in coronary heart disease].
    Mauser M; Voelker W; Ickrath O; Kühlkamp V; Karsch KR
    Dtsch Med Wochenschr; 1990 May; 115(19):723-9. PubMed ID: 2140095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antianginal and anti-ischemic efficacy of immediate-release nisoldipine in chronic stable angina pectoris.
    Glasser SP; Bittar N; Labreche DG; Singh B; Katz R; Schulman P
    Am J Cardiol; 1994 Jun; 73(16):1165-8. PubMed ID: 7911271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.